MK-677 or IGF-1 LR3 for a first GH-axis cycle?

MK-677, without hesitation. Much better tolerance profile, practical oral, raises GH/IGF-1 parameters in a physiological way (amplification of pulsatile endogenous secretion), no acute hypoglycemic risk. IGF-1 LR3 is more potent but much riskier (hypoglycemia, oncologic signal, non-targeted tissue growth). Start with MK-677 12-16 weeks to assess tolerance of moderately stimulated GH/IGF-1 axis. Serum IGF-1 panel mid-cycle.

Why does MK-677 increase appetite so much?

Direct mechanism via ghrelin receptor (GHSR1a) (Kojima 1999). Ghrelin is the orexigenic hormone (which stimulates appetite) secreted by the stomach. MK-677 mimics its action on hypothalamic appetite neurons, causing a marked increase in appetite, particularly in evening and night. Useful effect for users in caloric surplus struggling to reach their targets, troublesome in cut. Practical tip: bedtime intake to benefit from nocturnal GH peak and limit daytime impact of hunger.

Is IGF-1 LR3 really carcinogenic?

Concerning signal but not confirmed in humans in recreational use. Renehan 2008 documents a statistical association between elevated serum IGF-1 and risk of several solid cancers (prostate, breast, colon) in epidemiological cohorts. Mechanism: IGF-1 favors cell proliferation and inhibits apoptosis. No human RCT under recreational IGF-1 LR3 has confirmed an increased risk, due to lack of long studies. Precautionary principle: limit to short cycles, moderate doses, long breaks, regular screening in chronic users.

What IGF-1 elevation to expect under MK-677?

Nass 2008 documented +20-30% serum IGF-1 at 25 mg/d × 12 months in elderly. In young sporty user, amplitude is typically +30-50% at 25 mg/d × 12 weeks (more marked effect in subjects whose baseline IGF-1 is in the lower third). Serum IGF-1 monitoring mid-cycle to confirm response. If no elevation at 6 weeks, dose is probably underdosed or product not authentic.

Why inject IGF-1 LR3 post-workout?

To benefit from the anabolic post-exercise window and target trained muscles. The IGF-1 receptor is upregulated in muscle fibers damaged by training, so an injection 15-30 min after the session increases the local anabolic effect. Caution: always inject post-prandial with rapid carbs at hand to manage possible hypoglycemia. Never inject fasting. Injection site: intramuscular in trained muscle for local effect, or subcutaneous for systemic effect.

Does MK-677 cause insulin resistance?

Mild and reversible on cessation. Nass 2008 observed modest fasting glycemia elevation (+5-10 mg/dL) and HbA1c (+0.1-0.2%) at 12 months under 25 mg/d. Mechanism: sustained GH/IGF-1 elevation reduces hepatic insulin sensitivity. Generally not clinically significant effect in young and healthy subjects, but to monitor in users predisposed to diabetes. Fasting glycemia and HbA1c panel at W0, W12, W24 of the cycle.

Does IGF-1 LR3 really enlarge organs?

Possible in chronic high-dose users. Holt 2008 and the endocrine literature document organ growth (acromegaly-like: liver, spleen, heart, intestine) under chronically elevated systemic IGF-1. More marked effect in users of HGH + IGF-1 LR3 combined. Short cycles (4-6 weeks) and long breaks limit this risk. Abdominal ultrasound and echocardiography monitoring in chronic use. It is the characteristic 'gut' effect of post-2000 professional bodybuilders.

MK-677 or HGH to raise IGF-1?

HGH is more potent in IGF-1 elevation (+50-200% depending on dose) but much more expensive, injectable several times per week, and with its own risks (insulin resistance, carpal tunnel syndrome, tissue growth). MK-677 is oral, affordable, raises IGF-1 +20-50% physiologically by amplifying endogenous secretion. For user seeking moderate long-term GH-axis effect, MK-677 has better cost/benefit ratio. For maximum effect with substantial budget, HGH remains superior.

MK-677 vs IGF-1 LR3: complete comparison (oral GH-mimetic vs direct peptide)

Critère	mk-677	igf-1-lr3
Class	Oral GH secretagogue	Injectable IGF-1 analog
Route	Oral (morning)	SC or IM
Half-life	~6 h	~24 h
Mechanism	Endogenous GH stimulation	Direct IGF-1 action
Increased appetite	Marked	Moderate
Water retention	Marked	Moderate
Typical dose	10-25 mg/d	20-80 µg/d
Hypoglycemia risk	Low	High (rapid post-inj action)

Quand choisir mk-677

MK-677 (ibutamoren) is an oral GH secretagogue acting via the ghrelin receptor (GHSR1a), stimulating endogenous GH release from the pituitary (Nass 2008: RCT in elderly, +20% serum IGF-1 in 1 year at 25 mg/d). Choose it for: (1) a sustained elevation of the GH/IGF-1 axis without injection, (2) improvement of body composition on long cycle (12-24 weeks), (3) support for sleep recovery and skin quality, (4) a complement to an AAS cycle for typical GH/IGF-1 effects. Pharmacological profile (Sigalos 2018, Kojima 1999): orally active, action via ghrelin receptor, half-life ~6 h but biological effect of 24 h thanks to amplification of GH pulsatile secretion. Drawbacks to anticipate (Pope 2014): drastically increased appetite (the effect on ghrelin is powerful), sometimes marked water retention, slight insulin resistance on long cycle (Nass 2008: modest elevation of fasting glycemia at 12 months), occasional extremity numbness. Typical dose 10-25 mg/d in single intake in the evening (to benefit from nocturnal GH peak). No PCT needed (non-androgenic mechanism). Long cycle 12-24 weeks possible.

Quand choisir igf-1-lr3

IGF-1 LR3 is a long-duration analog of native IGF-1 (Long R3 IGF-1, N-terminal modification that reduces IGFBP binding and prolongs serum half-life to ~24 h vs ~10 min for native IGF-1). Tomas 1992 demonstrated in rat a specific anabolic and anti-catabolic effect, distinct from that of GH. Choose it for: (1) a targeted and powerful action on the IGF-1 receptor, (2) a mass cycle in complement to AAS, (3) local injections to stimulate growth in specific muscles. Pharmacological profile: injectable peptide (SC or IM), high affinity to IGF-1 receptor, partially escapes IGFBP regulation. Major drawbacks to anticipate (Holt 2008, Renehan 2008): acute post-injection hypoglycemia (IGF-1 has insulin-like activity, risk of severe hypoglycemic crisis if taken fasting), non-selective tissue growth (internal organs, cartilaginous tissues), concerning oncologic signal (IGF-1 favors cell proliferation, Renehan 2008 study: association elevated serum IGF-1 and risk of several solid cancers). Typical dose 20-80 µg/d post-workout to target the trained muscle. Short cycles (4-6 weeks), long breaks.

Combinaison ?

The MK-677 + IGF-1 LR3 combo stimulates both GH pathway and IGF-1 pathway but must be approached with caution. Scheme: MK-677 25 mg/d × 12 weeks in background (mild and sustained effect on GH/IGF-1 axis), with a short IGF-1 LR3 cycle (30-50 µg/d × 4 weeks) post-workout during weeks 4-8 for targeted stimulation. Always on AAS testosterone base 300-500 mg/week that synergizes with the GH/IGF-1 axis (additive anabolic effect). Biological monitoring: fasting glycemia and HbA1c at W0, W6, W12 (both compounds can alter insulin sensitivity), serum IGF-1 to calibrate doses, lipids, BP. Subjective monitoring: numbness, carpal tunnel syndrome (tissue fluid retention), post-IGF-1 injection hypoglycemia (always inject post-prandial with carbs at hand). Theoretical cumulative oncologic risk: limit this type of combo to specific competitive windows, not in routine. Sample 12-week GH-axis timeline: W0 baseline IGF-1 + glycemia + HbA1c + lipids, W2 first subjective assessment (sleep quality, appetite), W4 IGF-1 recheck (should be rising), W6 mid-cycle full panel, W8 IGF-1 + glycemia (insulin sensitivity check), W10 final lipids and BP, W12 stop both compounds, W16 follow-up panel. MK-677 appetite management practical tip: bedtime dosing minimizes daytime hunger and aligns with natural GH peak — morning dosing increases overall caloric intake which may not align with goals. IGF-1 LR3 hypoglycemia management: always inject post-workout with 30 g of fast carbs ready (juice, dextrose, dates) in case of acute drop — never inject fasted or before driving. Sample baseline panel must include IGF-1 (the primary biomarker), fasting glucose and HbA1c (both compounds affect insulin sensitivity), lipids, T total (no direct effect but useful for general health context), and resting BP averaged over three days. Echocardiography recommended at baseline and annually for chronic users due to documented organ growth signal under sustained IGF-1 elevation.

FAQ

MK-677 or IGF-1 LR3 for a first GH-axis cycle?: MK-677, without hesitation. Much better tolerance profile, practical oral, raises GH/IGF-1 parameters in a physiological way (amplification of pulsatile endogenous secretion), no acute hypoglycemic risk. IGF-1 LR3 is more potent but much riskier (hypoglycemia, oncologic signal, non-targeted tissue growth). Start with MK-677 12-16 weeks to assess tolerance of moderately stimulated GH/IGF-1 axis. Serum IGF-1 panel mid-cycle.
Why does MK-677 increase appetite so much?: Direct mechanism via ghrelin receptor (GHSR1a) (Kojima 1999). Ghrelin is the orexigenic hormone (which stimulates appetite) secreted by the stomach. MK-677 mimics its action on hypothalamic appetite neurons, causing a marked increase in appetite, particularly in evening and night. Useful effect for users in caloric surplus struggling to reach their targets, troublesome in cut. Practical tip: bedtime intake to benefit from nocturnal GH peak and limit daytime impact of hunger.
Is IGF-1 LR3 really carcinogenic?: Concerning signal but not confirmed in humans in recreational use. Renehan 2008 documents a statistical association between elevated serum IGF-1 and risk of several solid cancers (prostate, breast, colon) in epidemiological cohorts. Mechanism: IGF-1 favors cell proliferation and inhibits apoptosis. No human RCT under recreational IGF-1 LR3 has confirmed an increased risk, due to lack of long studies. Precautionary principle: limit to short cycles, moderate doses, long breaks, regular screening in chronic users.
What IGF-1 elevation to expect under MK-677?: Nass 2008 documented +20-30% serum IGF-1 at 25 mg/d × 12 months in elderly. In young sporty user, amplitude is typically +30-50% at 25 mg/d × 12 weeks (more marked effect in subjects whose baseline IGF-1 is in the lower third). Serum IGF-1 monitoring mid-cycle to confirm response. If no elevation at 6 weeks, dose is probably underdosed or product not authentic.
Why inject IGF-1 LR3 post-workout?: To benefit from the anabolic post-exercise window and target trained muscles. The IGF-1 receptor is upregulated in muscle fibers damaged by training, so an injection 15-30 min after the session increases the local anabolic effect. Caution: always inject post-prandial with rapid carbs at hand to manage possible hypoglycemia. Never inject fasting. Injection site: intramuscular in trained muscle for local effect, or subcutaneous for systemic effect.
Does MK-677 cause insulin resistance?: Mild and reversible on cessation. Nass 2008 observed modest fasting glycemia elevation (+5-10 mg/dL) and HbA1c (+0.1-0.2%) at 12 months under 25 mg/d. Mechanism: sustained GH/IGF-1 elevation reduces hepatic insulin sensitivity. Generally not clinically significant effect in young and healthy subjects, but to monitor in users predisposed to diabetes. Fasting glycemia and HbA1c panel at W0, W12, W24 of the cycle.
Does IGF-1 LR3 really enlarge organs?: Possible in chronic high-dose users. Holt 2008 and the endocrine literature document organ growth (acromegaly-like: liver, spleen, heart, intestine) under chronically elevated systemic IGF-1. More marked effect in users of HGH + IGF-1 LR3 combined. Short cycles (4-6 weeks) and long breaks limit this risk. Abdominal ultrasound and echocardiography monitoring in chronic use. It is the characteristic 'gut' effect of post-2000 professional bodybuilders.
MK-677 or HGH to raise IGF-1?: HGH is more potent in IGF-1 elevation (+50-200% depending on dose) but much more expensive, injectable several times per week, and with its own risks (insulin resistance, carpal tunnel syndrome, tissue growth). MK-677 is oral, affordable, raises IGF-1 +20-50% physiologically by amplifying endogenous secretion. For user seeking moderate long-term GH-axis effect, MK-677 has better cost/benefit ratio. For maximum effect with substantial budget, HGH remains superior.

MK-677 vs IGF-1 LR3: complete comparison (oral GH-mimetic vs direct peptide)

Critère	mk-677	igf-1-lr3
Class	Oral GH secretagogue	Injectable IGF-1 analog
Route	Oral (morning)	SC or IM
Half-life	~6 h	~24 h
Mechanism	Endogenous GH stimulation	Direct IGF-1 action
Increased appetite	Marked	Moderate
Water retention	Marked	Moderate
Typical dose	10-25 mg/d	20-80 µg/d
Hypoglycemia risk	Low	High (rapid post-inj action)

Quand choisir mk-677

Quand choisir igf-1-lr3

Combinaison ?

FAQ

MK-677 or IGF-1 LR3 for a first GH-axis cycle?: MK-677, without hesitation. Much better tolerance profile, practical oral, raises GH/IGF-1 parameters in a physiological way (amplification of pulsatile endogenous secretion), no acute hypoglycemic risk. IGF-1 LR3 is more potent but much riskier (hypoglycemia, oncologic signal, non-targeted tissue growth). Start with MK-677 12-16 weeks to assess tolerance of moderately stimulated GH/IGF-1 axis. Serum IGF-1 panel mid-cycle.
Why does MK-677 increase appetite so much?: Direct mechanism via ghrelin receptor (GHSR1a) (Kojima 1999). Ghrelin is the orexigenic hormone (which stimulates appetite) secreted by the stomach. MK-677 mimics its action on hypothalamic appetite neurons, causing a marked increase in appetite, particularly in evening and night. Useful effect for users in caloric surplus struggling to reach their targets, troublesome in cut. Practical tip: bedtime intake to benefit from nocturnal GH peak and limit daytime impact of hunger.
Is IGF-1 LR3 really carcinogenic?: Concerning signal but not confirmed in humans in recreational use. Renehan 2008 documents a statistical association between elevated serum IGF-1 and risk of several solid cancers (prostate, breast, colon) in epidemiological cohorts. Mechanism: IGF-1 favors cell proliferation and inhibits apoptosis. No human RCT under recreational IGF-1 LR3 has confirmed an increased risk, due to lack of long studies. Precautionary principle: limit to short cycles, moderate doses, long breaks, regular screening in chronic users.
What IGF-1 elevation to expect under MK-677?: Nass 2008 documented +20-30% serum IGF-1 at 25 mg/d × 12 months in elderly. In young sporty user, amplitude is typically +30-50% at 25 mg/d × 12 weeks (more marked effect in subjects whose baseline IGF-1 is in the lower third). Serum IGF-1 monitoring mid-cycle to confirm response. If no elevation at 6 weeks, dose is probably underdosed or product not authentic.
Why inject IGF-1 LR3 post-workout?: To benefit from the anabolic post-exercise window and target trained muscles. The IGF-1 receptor is upregulated in muscle fibers damaged by training, so an injection 15-30 min after the session increases the local anabolic effect. Caution: always inject post-prandial with rapid carbs at hand to manage possible hypoglycemia. Never inject fasting. Injection site: intramuscular in trained muscle for local effect, or subcutaneous for systemic effect.
Does MK-677 cause insulin resistance?: Mild and reversible on cessation. Nass 2008 observed modest fasting glycemia elevation (+5-10 mg/dL) and HbA1c (+0.1-0.2%) at 12 months under 25 mg/d. Mechanism: sustained GH/IGF-1 elevation reduces hepatic insulin sensitivity. Generally not clinically significant effect in young and healthy subjects, but to monitor in users predisposed to diabetes. Fasting glycemia and HbA1c panel at W0, W12, W24 of the cycle.
Does IGF-1 LR3 really enlarge organs?: Possible in chronic high-dose users. Holt 2008 and the endocrine literature document organ growth (acromegaly-like: liver, spleen, heart, intestine) under chronically elevated systemic IGF-1. More marked effect in users of HGH + IGF-1 LR3 combined. Short cycles (4-6 weeks) and long breaks limit this risk. Abdominal ultrasound and echocardiography monitoring in chronic use. It is the characteristic 'gut' effect of post-2000 professional bodybuilders.
MK-677 or HGH to raise IGF-1?: HGH is more potent in IGF-1 elevation (+50-200% depending on dose) but much more expensive, injectable several times per week, and with its own risks (insulin resistance, carpal tunnel syndrome, tissue growth). MK-677 is oral, affordable, raises IGF-1 +20-50% physiologically by amplifying endogenous secretion. For user seeking moderate long-term GH-axis effect, MK-677 has better cost/benefit ratio. For maximum effect with substantial budget, HGH remains superior.